DavidGeorgeMaloneyMD

Oncology • Seattle, WA

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Maloney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maloney's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-667-5616

Fax+1 206-667-6124

Summary

Dr. David Maloney is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance, Seattle Children's Hospital, and University of Washington Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice 32 years. He specializes in hematologic oncology and is experienced in hematologic oncology.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1994
Brigham and Women's HospitalResidency, Internal Medicine, 1985 - 1988
Stanford University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1988 - Present
WA State Medical License 1994 - 2024
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation Start of enrollment: 1996 Mar 01
Completed
Phase 1
High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1995 Oct 01
Completed
Phase 1
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma Start of enrollment: 1997 Sep 01
Completed
Not Applicable
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma Start of enrollment: 1999 Mar 01
Completed
Phase 1, Phase 2
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Start of enrollment: 1999 Sep 01
Completed
Phase 1, Phase 2
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2000 Oct 01
Terminated
Phase 3
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Start of enrollment: 2000 Dec 01
Completed
Not Applicable
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Start of enrollment: 2013 May 22
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

267 citations
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning
Frédéric Baron, Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, Mohamed L. Sorror
Journal of Clinical Oncology. 2005-03-20
1453 citations
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, Laïla Aïcha Hanafi, Carolina Berger, Ted Gooley, Sindhu Cherian
The Journal of Clinical Investigation. 2016-06-01
262 citations
Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and M...
Mohamed L. Sorror, Sergio Giralt, Brenda M. Sandmaier, Marcos de Lima, Munir Shahjahan
Blood. 2007-12-15

Journal Articles

Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy with CD19 CAR-T Cells
Mark Wurfel, David G Maloney, Kathleen R Fink, W Conrad Liles, Cameron J Turtle, Cecilia Yeung, Clinical Cancer Research

Abstracts/Posters

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressiv...
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Late Effects of CD19-Targeted CAR-T Cell Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes
60th American Society of Hematology Annual Meeting - 11/30/2018
Stem Cell Transplant and Immunotherapy in Acute Lymphoblastic Leukemia: Foes or Friends?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Highlights from Day 2: Addressing Challenges in CAR-T Therapy for ALL, AML, CLL & More…June 6th, 2022
Northside Hospital Opens Fifth Health Choice Urgent Care Center in Chamblee, GeorgiaNovember 10th, 2021
Live ’N Learn SMILE Child Care Center Celebrates Thirty YearsAugust 3rd, 2021
Join now to see all

Grant Support

Allogeneic HCT For Hematologic Malignancies: Pharmacologic ManipulationsNational Cancer Institute2009–2012
Mixed Chimerism In The Treatment Of B-Cell MalignanciesNational Cancer Institute2004–2008
Anti-Cd20 Antibody Therapy Of Nhl-- Mechanism Of ActionNational Cancer Institute2000–2002
Myeloma Idiotype VaccinesNational Cancer Institute1997